Increasing evidence supports a close relationship between Ras-ERK1/2 activation in the striatum and L-DOPA-induced dyskinesia (LID). ERK1/2 activation by L-DOPA takes place through the crosstalk between D1R/AC/PKA/DARPP-32 pathway and NMDA/Ras pathway. Compelling genetic and pharmacological evidence indicates that Ras-ERK1/2 inhibition prevents LID onset and may even revert already established dyskinetic symptoms. However, it is currently unclear whether exacerbation of Ras-ERK1/2 activity in the striatum may further aggravate dyskinesia in experimental animal models. Here we took advantage of two genetic models in which Ras-ERK1/2 signaling is hyperactivated, the Nf1 +/− mice, in which the Ras inhibitor neurofibromin is reduced, and the Ras-GRF1 overexpressing (Ras-GRF1 OE) transgenic mice in which a specific neuronal activator of Ras is enhanced. Nf1 +/− and Ras-GRF1 OE mice were unilaterally lesioned with 6-OHDA and treated with an escalating L-DOPA dosing regimen. In addition, a subset of Nf1 +/− hemi-parkinsonian animals was also co-treated with the Ras inhibitor lovastatin. Our results revealed that Nf1 +/− and Ras-GRF1 OE mice displayed similar dyskinetic symptoms to their wild-type counterparts. This observation was confirmed by the lack of differences between mutant and wild-type mice in striatal molecular changes associated to LID (i.e., FosB, and pERK1/2 expression). Interestingly, attenuation of Ras activity with lovastatin does not weaken dyskinetic symptoms in Nf1 +/− mice. Altogether, these data suggest that ERK1/2-signaling activation in dyskinetic animals is maximal and does not require further genetic enhancement in the upstream Ras pathway. However, our data also demonstrate that such a genetic enhancement may reduce the efficacy of anti-dyskinetic drugs like lovastatin.
Results
Basal locomotor activity and motor coordination are normal in Nf1 +/− mutant mice. In order to rule out any baseline motor impairment in the mutant mice, we carried out spontaneous locomotor activity and rotarod tests prior to the 6-OHDA lesion. Since previous experiments from Fasano and colleagues 37 demonstrated that the increase of Ras-GRF1 expression in Ras-GRF1 OE mice does not affect locomotor activity and motor coordination in these animals, we focused on testing these behavioral performances in Nf1 +/− mice. Nf1 +/− and wild-type (WT) mice showed similar horizontal and vertical activity, as indicated by the number of beam breaks measured in a multi-cage activity meter system (Fig. 1A,B ). Ambulatory activity measured as total distance traveled was also similar in both genotypes (Fig. 1C) . Likewise, there were no statistically significant differences between genotypes in motor coordination (Fig. 1D) , measured as the latency to fall from the rotarod. These results indicated that alterations in Nf1 gene expression do not modify spontaneous locomotor activity or motor coordination.
Nf1 +/− mutant mice show high striatal Ras-GTP levels but reduced cAMP levels. Next, to confirm that Nf1 +/− mice showed a higher activation of the Ras-ERK1/2 signaling pathway, we studied striatal Ras-GTP levels in naïve animals. As expected, we found that Nf1 +/− mice displayed higher levels of Ras-GTP compared to WT mice ( Fig. 1E and supplementary Fig. S1 ). We also examined whether the mutation in neurofibromin could modulate the activity of Gαolf protein by testing cAMP levels in the striatum. Interestingly, we found a decrease in cAMP levels in Nf1 +/− mutant mice relative to WT counterparts ( Fig. 1F ).
Heterozygous deletion of Nf1 has no effect on L-DOPA-induced dyskinesia or LID-associated changes in gene expression. To explore the role of Nf1 in dyskinesia, we studied the development of LID in hemiparkinsonian/6-OHDA-lesioned mice by scoring axial dystonia and forelimb and orofacial dyskinesias in Nf1 +/− and their WT littermates. Since high L-DOPA doses can mask subtle differences between genotypes, we used an escalating dosing regimen in which L-DOPA was given i.p. daily for 9 days, with the daily dose increasing over the course of treatment (5, 10, and 20 mg/kg i.p., 3 consecutive days at each dose).
Daily scoring of AIMs (abnormal involuntary movements, i.e., axial dystonia, forelimb and orofacial dyskinesia) revealed a gradual development of dyskinesia in both genotypes, with AIMs scores increasing as the L-DOPA dose ascended. Interestingly, heterozygous Nf1 mutation had no effect on dyskinetic scores at any of the three L-DOPA doses: there were no significant differences in total dyskinetic scores between Nf1 +/− and WT mice across the 9-day L-DOPA treatment ( Fig. 2D ). Both transgenic and WT mice showed great lateral deviation, twisted posture, contralateral forelimb dyskinesia, and jaw movements with tongue protrusion, with no statistically significant differences between genotypes for any of the three AIMs subtypes ( Fig. 2A,C) .
Correlating with these behavioral results, analysis of the dorsolateral striatum showed that L-DOPA-induced expression of FosB and pERK1/2 were similar in both genotypes (Fig. 3A) , as well as pAcH3 expression (data not shown). The percentage of denervated striatum also demonstrated no different denervation between groups (Fig. 3B ,B′).
Overexpression of Ras-GRF1 does not affect L-DOPA-induced dyskinesia. We next explored the effects of direct intervention in Ras signaling by using Ras-GRF1 overexpressing (Ras-GRF1 OE) mice 37, 38 . Ras-GRF1 protein levels in these animals are threefold higher than in WT. Importantly, we previously shown that Ras-GRF1 OE mice are more sensitive to cocaine as measured by enhanced ERK1/2 activation in the striatum and increased behavioral responses 37 . Similarly to Nf1 +/− mice, Ras-GRF1 OE animals showed dyskinetic symptoms Lovastatin attenuates L-DOPA-induced dyskinesia severity in WT but not in Nf1 +/− mice. To assess the effect of pharmacological blockade of Ras on LID we used lovastatin, a Ras activity inhibitor. Mice were pretreated with lovastatin (20 mg/kg i.p.) or 0.9% saline for 3 days, as previously described 23 . Afterwards, for 10 consecutive days, mice received 20 mg/kg of L-DOPA 2.5 h after lovastatin or saline administration. The time course of AIMs expression following 20 mg/kg L-DOPA treatment was similar in Nf1 +/− and WT mice ( Fig. 5A ). Dyskinesia was evident at 20 minutes, peaked between 40 and 60 minutes, declined significantly by 100-120 minutes, and disappeared after 140-160 minutes for both genotypes. WT mice treated with both drugs exhibited significantly less dyskinesia than those treated with L-DOPA only. In contrast, lovastatin had no effect on the intensity of LID in Nf1 +/− transgenic mice. This difference was reflected in cumulative AIMs scores over the entire 160-min observation period ( Fig. 5B ). Those scores were reduced by lovastatin in WT mice but not in Nf1 +/− . Analysis of the individual AIMs over the entire 160-min observation revealed that the effect of lovastatin in WT mice was evident in all the dyskinetic sub-symptoms ( Fig. 5C ). Intriguingly, lovastatin did not modify frequency or intensity of any individual dyskinetic symptoms in the Nf1 +/− mutant mice.
To exclude any possible interaction of Nf1 mutation on the antiparkinsonian properties of L-DOPA, we performed the rotarod test before and after the L-DOPA treatment. In the absence of L-DOPA, parkinsonian animals of both WT and Nf1 +/− genotypes showed similar latencies to fall from the rotating rod ( Fig. 5D ), while under chronic L-DOPA treatment both groups of mice showed an improved motor performance, indicating a similar therapeutic response to L-DOPA. 
Discussion
The major finding of this study is that the onset and expression of LID in Nf1 +/− and in Ras-GRF1 OE mice are indistinguishable from WT. This indicates that a genetic enhancement of the Ras-ERK1/2 pathway does not result in either an exacerbated dyskinetic behavior or in the increase of the associated molecular markers (i.e. FosB, pERK1/2 and pAcH3 expression). Moreover, we demonstrate that pharmacological inhibition of Ras function with lovastatin decreases dyskinetic signs in WT mice, although is unable to reduce LID in the Nf1 +/− mice.
Since previous works indicate that there is a correlation between Ras-ERK1/2 activity levels and intensity of dyskinetic symptoms 1, 2, 6, 8, 39 , we expected that Nf1 +/− and Ras-GRF1 OE mice would exhibit more dyskinesia than WT animals. However, this increase in dyskinetic symptoms is not evident in our transgenic mice, nor is an increase in the molecular changes induced by L-DOPA.
As expected, Nf1 +/− mice showed higher striatal Ras-GTP levels compared to their WT littermates, due to the heterozygous deletion of Nf1 gene. In heterozygosis, neurofibromin is less efficient at converting Ras-GTP to its inactive form Ras-GDP, leading to higher levels of Ras-GTP as depicted in Fig. 6 . On the other hand, this increase in the Ras-ERK1/2 signaling pathway seems to be counterbalanced by a decrease in the Gαolf-cAMP pathway, indicated by the lower cAMP striatal levels we found in Nf1 +/− mice. These results are in line with those found in both Nf1 patient-derived induced pluripotent stem cell-neural progenitor cells and mouse Nf1 +/− hippocampal neurons 40 . Thus, we speculate that dyskinetic Nf1 +/− mice have the Ras-ERK1/2 pathway increased and the Gαolf-cAMP pathway decreased in the striatum, generating a net effect similar to that found in WT animals and is responsible for the same dyskinetic behavior displayed. Moreover, a similar scenario could be found in the Ras-GRF1 OE mice since these animals have also increased Ras activity similar to that of the Nf1 +/− mice. Future experiments to examine striatal cAMP activity in these mice may corroborate this idea.
Despite these negative results, we found that decreasing Ras activity with lovastatin decreases LID in WT mice but not in Nf1 +/− mice. Chronic co-treatment with lovastatin and L-DOPA effectively decreases dyskinetic symptoms in WT mice, consistent with previous work in hemiparkinsonian rats 23 . In our study, we demonstrate that the lovastatin-induced Ras-signaling pathway inhibition significantly reduced all AIMs in WT mice. These results are in line with previous findings using Ras-GRF1 knockout mice 5 , which also showed a decrease in LID. Taken together, this indicates that a direct inhibition in the Ras-ERK1/2 pathway is enough to reduce LID symptoms, but not to abolish them, as occurs when the D1R pathway is altered by a genetic ablation of D1R 4 . NMDA receptor antagonists do not modify ERK1/2 phosphorylation induced by D1R agonists in the denervated striatum 41 . Thus, these data suggest that D1R plays a more important role than the NMDA receptor in the control of ERK cascade following chronic L-DOPA treatment. However, it is also important to consider that metabotropic glutamate receptor type 5 (mGluR5) modulates D1R signaling pathway via ERK1/2 activation in the denervated striatum [42] [43] [44] . For instance, local infusion of a mGluR5 antagonist into the denervated striatum in hemiparkinsonian rats reduced D1R-agonist induced ERK1/2 signaling 42 .
In contrast with that found in WT animals, chronic administration of lovastatin did not diminish LID in transgenic Nf1 +/− mice, which have upregulated Ras function. Thus, lovastatin Ras-inhibition is not sufficient to reduce dyskinetic symptoms in these mice. These results are in line with previous findings which showed that Ras inhibitors can rescue only some phenotypes in Nf1-deficient cell lines 45 and that lovastatin cannot correct the behavioral or the PET imaging deficits in mice 46 . More recently, Payne and colleagues 47 performed the last and largest statin study in children with NF1 and concluded that lovastatin is not an effective treatment for cognitive or behavioral deficits in this population. At the signaling level, previous work in vitro with hippocampal neurons from Nf1 +/− mice showed that continuous lovastatin exposure normalizes both the attenuated cAMP levels and increased Ras activity in these mutant cells 40 . Thus, lovastatin decreases LID in WT animals by decreasing Ras activity, while in Nf1 +/− mice, although it decreases Ras activity, does not change LID, possibly because it may increase cAMP with a null net effect.
Finally, previous experiments demonstrated that the increased Ras-GRF1 expression in Ras-GRF1 OE mice does not affect locomotor activity and motor coordination 37 . Here we tested these behaviors in Nf1 +/− mice and found that these animals are indistinguishable from their WT littermates in motor activity and motor coordination, in agreement with previous observations in the open field test 33 and the water maze focusing on swimming speed and other motor skills 33 (for review see 48 ). Since spontaneous locomotor activity and motor coordination are normal in the Nf1 +/− mice, results of dyskinesia experiments are not due to motor impairment, but rather to the modification of Nf1-related molecular pathways. Importantly, genetic modification in Nf1 +/− mice does not alter the kinetic profile of L-DOPA, as all animals show similar duration of the L-DOPA response and display similar performance skills in the rotarod test, demonstrating that the antiparkinsonian efficacy of L-DOPA is preserved in all the animals.
In conclusion, it appears from the present study that a plateau in ERK1/2-signaling activation may already be achieved in response to denervation and L-DOPA treatment, therefore a genetic enhancement of the Ras pathway does not exacerbate dyskinetic behavior. However, the lack of anti-dyskinetic effect in response to lovastatin observed in mice with abnormally high Ras activity may be of clinical significance since patients affected by such condition -RASopathies -do exist and may be tested in this respect in the near future.
Methods and Materials
Animals. Since the Nf1 null mouse is lethal 35, 49 , we used heterozygous mice for the Nf1 gene (Nf1 +/− ) 27 obtained by heterozygous mating and genotyped by PCR. Their WT littermates were used as controls. These Nf1 +/− mutant mice do not develop any abnormalities and are commonly used to study the role of neurofibromin. Ras-guanine nucleotide-releasing factor 1 overexpressing (Ras-GRF1 OE) mice, which exhibit a significant increase in p140 Ras−GRF1 protein (three folds to WT levels), were obtained as previously reported 37, 38 . Mice were housed under a 12-h light/dark cycle with ad libitum access to food. All experiments were performed in male and female 3-6 month old mice. Experimental protocols were approved by the Cajal Institute Committee on Human and Animal Experimentation and CSIC Ethics Committee, and were in accordance with guidelines of the European Union Council Directive (86/609/European Economic Community).
6-OHDA lesion and drug treatment.
Nf1 +/− mice and their WT littermates were anesthetized with 2% v/v isofluorane and received unilateral stereotaxic injections (2 × 2 μl) of 6-OHDA-HBr (5 μg/μl, 20 mM, containing 0.02% ascorbic acid, Sigma-Aldrich, St. Louis, Missouri, USA) in the left striatum at the following coordinates (mm from bregma): AP = +0.65, L = −2 and V = −4 and −3.5, as previously described 8, 50 . Ras-GRF1 OE mice and their WT littermates were lesioned by the administration of 1 μl of 6-OHDA-HBr in the right ascending medial forebrain bundle at the following coordinates: AP = −0.7, L = −1.2 and V = −4.7, as described 5 .
Establishment of L-DOPA-induced dyskinesia: escalating L-DOPA dosing regimen. After 3 weeks of recovery, a set of Nf1 +/− and WT animals were treated daily for 9 consecutive days with benserazide hydrochloride (10 mg/ kg i.p., Sigma-Aldrich), followed 20 minutes later by administration of L-DOPA methyl ester (Sigma-Aldrich), using an escalating dosing regimen with each dose administered for 3 consecutive days (5, 10 and 20 mg/kg i.p.). Similarly, Ras-GRF1 OE mice and their WT littermates were treated for 9 consecutive days with an escalating L-DOPA dosing regimen (3, 6 and 12 mg/kg i.p.) plus benserazide. In all cases control animals were treated daily with saline.
A second group of hemiparkinsonian Nf1 +/− mice was used to assess the effect of lovastatin on development of LID. Lovastatin (Mevinolin; Sigma-Aldrich), in the lactone form, was dissolved in ethanol and incubated at 50 °C in 0.1 N NaOH for 2 hours for the conversion to the sodium salt. Volume was adjusted with water and pH was adjusted to 7.5 with HCl 23,51 . 3-weeks after lesion, mice were pretreated with lovastatin (20 mg/kg i.p.) or 0.9% saline for 3 days. Afterwards, for 10 consecutive days, mice received 20 mg/kg of L-DOPA 2.5 h after lovastatin or saline administration.
Behavioral analysis. Locomotor activity and motor coordination.
Horizontal and vertical activities, as well as total distance traveled, were recorded in mice as described 52 . Motor coordination was measured using the rotarod (Ugo Basile, Italy) following an accelerating protocol, with increasing speed from 4 to 40 rpm over a 5 minute period as described 53 . Briefly, mice were tested in 6 consecutive trials 20 minutes apart. Motor coordination was tested before 6-OHDA lesion (naïve), 3 weeks after lesion (Parkinsonian state), and during L-DOPA treatment (dyskinetic state, ON L-DOPA) on day 14, 24 hours after the last L-DOPA injection to avoid overtraining and the peak dyskinesia 50, 54 .
Dyskinetic score. L-DOPA-induced dyskinesia was evaluated using a 0-4 severity scale previously established 5, 8, 55, 56 . Mice were placed in separate glass cylinders and AIMs were assessed daily for 1 minute (monitoring period) every 20 minutes after L-DOPA over a period of 2 h, or on day 13 in the lovastatin experiment. The total AIMs score is the sum of individual scores for each AIM subtype.
Immunohistochemistry and image analysis. Animals were sacrificed 1 hour after the last L-DOPA injection and perfused and fixed with 4% paraformaldehyde. Brains were cut into 30-µm-thick coronal sections and immunohistochemistry studies were carried out according to published procedures [57] [58] [59] Quantification of FosB, pAcH3 and pERK1/2 immunoreactivity was carried out by nucleus count with the "cell counter" plug-in in NIH ImageJ software 3, 5, 11 . The number of immunolabelled nuclei was determined in 5-9 animals per group, using 5 serial rostrocaudal sections per animal and 2 counting frames on the dorsolateral striatum per section (0.091 mm 2 each frame). Images were digitized with a light microscope (Leica, Heidelberg, Germany) under 40x objective. Before counting, images were threshold at a standardized gray-scale level, empirically determined by 2 different observers to allow detection of stained nuclei from low to high intensity, with suppression of very lightly stained nuclei. The data are presented as number of stained nuclei per mm 2 (mean ± SEM).
Quantification of TH immunoreactivity fibers in the striatum was performed with the NIH ImageJ software as previously described 13, 60 , analyzing 6-9 rostrocaudal striatal sections per animal. Briefly, 4x lens color images were converted into a gray scale and the area of staining (i.e., denervated area) was quantified as percentage of the total striatal area. Data are presented as the percentage of depletion of dopaminergic fibers. cAMP and Ras-GTP assay. All assays were performed on dissected striatum, snap-frozen in liquid nitrogen. cAMP levels were quantitated from tissue homogenized in 0.1 M HCl, using a cAMP HTRF kit (CisBio) following manufacturer's instructions.
Active Ras (Ras-GTP) was detected by Raf1-RBD immunoprecipitation using the RAS activation kit (Millipore). Briefly 500 µl of homogenized extract were incubated with Raf-1 RBD and agarose for 45 min at 4 °C. Then samples were centrifuged for 10 seconds at 14000 × g and agarose pellets were washed three times in the same conditions. Pellets were resuspended in 40 µL of 2X Laemli buffer supplemented with 2 mM DTT and boiled for 5 min at 100 °C. Samples were then processed for WB by following manufacturer's instructions. Total Ras was also detected as loading control. Both cAMP and Ras-GTP levels were normalized to the levels observed in the striatum of the WT group.
Statistical analysis.
Both the behavioral and immunolabeling quantification data of L-DOPA ascending-dose experiment were analyzed by one-way ANOVA. cAMP and Ras-GTP levels data were evaluated by unpaired t-test. Lovastatin experiment data were analyzed by two-way ANOVA followed by Student-Newman-Keuls post hoc test. Differences were considered statistically significant at p < 0.05.
